


PHARMACEUTICAL 2018



AGILE THERAPEUTICS INC Rank 163 of 342





PHARMACEUTICAL 2018



The relative strengths and weaknesses of AGILE THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGILE THERAPEUTICS INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 53% points. The greatest weakness of AGILE THERAPEUTICS INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 105%, being 60% points above the market average of 46%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 36,714 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 14,272 |
| Liabilities, Non-Current | 0 |
| Other Assets | 18 |
| Other Compr. Net Income | 0 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | -1,493 |
| Other Revenues | 0 |
| Property and Equipment | 13,863 |
| Research and Development | 14,428 |
| Selling, General and Administrative Expense | 12,383 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 50,595 |
| Liabilities | 14,272 |
| Expenses | 26,811 |
| Revenues | 0 |
| Stockholders Equity | 36,323 |
| Net Income | -28,304 |
| Comprehensive Net Income | -28,304 |
| Economic Capital Ratio | 105% |

